<p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO - 獲取免費報告）的股票被七家覆蓋該公司的研究機構一致評定為 “適度買入”，Marketbeat 報道稱。一位研究分析師給予該股票賣出評級，一位給予持有評級，四位給予買入評級，還有一位給予強烈買入評級。在過去一年中，更新該股票覆蓋的券商的平均一年目標價為 13.80 美元。</p>
<p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p>OBIO 已成為幾份分析師報告的主題。Chardan Capital 在 11 月 13 日的研究報告中重申了 “買入” 評級，並對 Orchestra BioMed 的股票設定了 20.00 美元的目標價。TD Cowen 在 12 月 10 日的報告中開始覆蓋 Orchestra BioMed 的股票，並給予該公司 “買入” 評級。最後，巴克萊在 1 月 9 日的報告中將 Orchestra BioMed 的目標價從 11.00 美元上調至 12.00 美元，並給予該股票 “超配” 評級。</p>
<p><strong>查看我們關於 OBIO 的最新研究報告</strong></p>
<h2>Orchestra BioMed 股票表現</h2>
<p>納斯達克：OBIO 週五開盤價為 3.92 美元。該公司的 50 日簡單移動平均為 4.16 美元，200 日簡單移動平均為 3.66 美元。Orchestra BioMed 的一年最低價為 2.20 美元，一年最高價為 5.42 美元。該公司的市值為 2.2134 億美元，市盈率為-2.15，貝塔值為 0.61。該公司的債務與股本比率為 0.32，流動比率為 4.73，速動比率為 4.72。</p>
<h2>機構投資者對 Orchestra BioMed 的看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Alyeska Investment Group L.P. 在第三季度購買了價值 338.6 萬美元的 Orchestra BioMed 新股份。Pathstone Holdings LLC 在第三季度獲得了 Orchestra BioMed 的新頭寸，價值 249.5 萬美元。Vanguard Group Inc. 在第三季度將其在 Orchestra BioMed 的持股增加了 28.0%。Vanguard Group Inc. 目前擁有 1481875 股該公司的股票，價值 367.5 萬美元，此前在上個季度購買了 324558 股。683 Capital Management LLC 在第四季度購買了價值約 84.7 萬美元的 Orchestra BioMed 新股份。最後，Marshall Wace LLP 在第四季度購買了價值 71.2 萬美元的 Orchestra BioMed 新股份。機構投資者和對沖基金持有該公司 53.20% 的股票。</p>
<h2>Orchestra BioMed 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Orchestra BioMed, Inc. 納斯達克：OBIO 是一家臨牀階段的生物製藥公司，致力於開發針對炎症、纖維化和腫瘤疾病的靶向療法。該公司的研究專注於新型小分子項目，旨在通過利用專有的前藥和靶向抑制劑平台來解決高未滿足需求的疾病。Orchestra BioMed 的產品線包括主要候選藥物 OBI-3424，這是一種由 AKR1C3 激活的前藥，用於治療特定的實體腫瘤，以及旨在抑制病理性炎症和纖維化的下一代調節劑。</p>
<p>Orchestra BioMed 在北美進行早期和中期臨牀研究，與關鍵意見領袖和學術中心緊密合作，以推進其項目。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Orchestra BioMed</li>
<li>~1.5 萬億美元的 SpaceX IPO：首次公開募股機會</li>
<li>美國的 1776 再次發生</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>家族信託如何幫助保護您的財富</li>
<li>這讓我感到憤怒</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1000 美元在 Orchestra BioMed 嗎？</h2>
<p>在您考慮 Orchestra BioMed 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Orchestra BioMed 並不在名單上。</p>
<p>雖然 Orchestra BioMed 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OBIO

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做空 - Direxion

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

<p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO）獲得了七家研究公司的 “適度買入” 共識評級。評級包括一項賣出、一項持有、四項買入和一項強力買入。平均目標價為 13.80 美元，Chardan Capital 設定的目標價為 20.00 美元。該股票開盤價為 3.92 美元，市值為 2.2134 億美元。機構投資者持有該公司 53.20% 的股份，該公司專注於開發針對炎症和腫瘤疾病的療法</p>

<p>Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the seven research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.80.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO - 獲取免費報告）的股票被七家覆蓋該公司的研究機構一致評定為 “適度買入”，Marketbeat 報道稱。一位研究分析師給予該股票賣出評級，一位給予持有評級，四位給予買入評級，還有一位給予強烈買入評級。在過去一年中，更新該股票覆蓋的券商的平均一年目標價為 13.80 美元。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p>OBIO has been the subject of several analyst reports. Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, November 13th. TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a &#34;buy&#34; rating for the company. Finally, Barclays lifted their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, January 9th.</p>
<div class="lb-trans"><p>OBIO 已成為幾份分析師報告的主題。Chardan Capital 在 11 月 13 日的研究報告中重申了 “買入” 評級，並對 Orchestra BioMed 的股票設定了 20.00 美元的目標價。TD Cowen 在 12 月 10 日的報告中開始覆蓋 Orchestra BioMed 的股票，並給予該公司 “買入” 評級。最後，巴克萊在 1 月 9 日的報告中將 Orchestra BioMed 的目標價從 11.00 美元上調至 12.00 美元，並給予該股票 “超配” 評級。</p>
</div><p><strong>Check Out Our Latest Research Report on OBIO</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 OBIO 的最新研究報告</strong></p>
</div><h2>Orchestra BioMed Stock Performance</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票表現</h2>
</div><p>NASDAQ:OBIO opened at $3.92 on Friday. The firm has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $3.66. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The firm has a market cap of $221.34 million, a PE ratio of -2.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72.</p>
<div class="lb-trans"><p>納斯達克：OBIO 週五開盤價為 3.92 美元。該公司的 50 日簡單移動平均為 4.16 美元，200 日簡單移動平均為 3.66 美元。Orchestra BioMed 的一年最低價為 2.20 美元，一年最高價為 5.42 美元。該公司的市值為 2.2134 億美元，市盈率為-2.15，貝塔值為 0.61。該公司的債務與股本比率為 0.32，流動比率為 4.73，速動比率為 4.72。</p>
</div><h2>Institutional Investors Weigh In On Orchestra BioMed</h2>
<div class="lb-trans"><h2>機構投資者對 Orchestra BioMed 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in shares of Orchestra BioMed during the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC acquired a new position in Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. increased its position in shares of Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $847,000. Finally, Marshall Wace LLP bought a new stake in Orchestra BioMed in the 4th quarter valued at $712,000. Institutional investors and hedge funds own 53.20% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Alyeska Investment Group L.P. 在第三季度購買了價值 338.6 萬美元的 Orchestra BioMed 新股份。Pathstone Holdings LLC 在第三季度獲得了 Orchestra BioMed 的新頭寸，價值 249.5 萬美元。Vanguard Group Inc. 在第三季度將其在 Orchestra BioMed 的持股增加了 28.0%。Vanguard Group Inc. 目前擁有 1481875 股該公司的股票，價值 367.5 萬美元，此前在上個季度購買了 324558 股。683 Capital Management LLC 在第四季度購買了價值約 84.7 萬美元的 Orchestra BioMed 新股份。最後，Marshall Wace LLP 在第四季度購買了價值 71.2 萬美元的 Orchestra BioMed 新股份。機構投資者和對沖基金持有該公司 53.20% 的股票。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.</p>
<div class="lb-trans"><p>Orchestra BioMed, Inc. 納斯達克：OBIO 是一家臨牀階段的生物製藥公司，致力於開發針對炎症、纖維化和腫瘤疾病的靶向療法。該公司的研究專注於新型小分子項目，旨在通過利用專有的前藥和靶向抑制劑平台來解決高未滿足需求的疾病。Orchestra BioMed 的產品線包括主要候選藥物 OBI-3424，這是一種由 AKR1C3 激活的前藥，用於治療特定的實體腫瘤，以及旨在抑制病理性炎症和纖維化的下一代調節劑。</p>
</div><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p>
<div class="lb-trans"><p>Orchestra BioMed 在北美進行早期和中期臨牀研究，與關鍵意見領袖和學術中心緊密合作，以推進其項目。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>This makes me furious</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Orchestra BioMed</li>
<li>~1.5 萬億美元的 SpaceX IPO：首次公開募股機會</li>
<li>美國的 1776 再次發生</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>家族信託如何幫助保護您的財富</li>
<li>這讓我感到憤怒</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1000 美元在 Orchestra BioMed 嗎？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Orchestra BioMed 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Orchestra BioMed 並不在名單上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Orchestra BioMed 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat

Orchestra BioMed

Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO）被券商一致評為 “適度買入”